Asosiy kontentga oʻtish
Boshqa

Identification of c- <i>MYC</i> as a Target of the APC Pathway

Tong‐Chuan HeJohns Hopkins MedicineAndrew B. SparksT.-C. He, C. Rago, B. Vogelstein, Howard Hughes Medical Institute and Johns Hopkins Oncology Center, 424 North Bond Street, Baltimore, MD 21231, USA. A. B. Sparks, H. Hermeking, L. Zawel, K. W. Kinzler, Johns Hopkins Oncology Center, Baltimore, MD 21231, USA. L. T. da Costa, Program in Human Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. P. J. Morin, National Institute on Aging, Baltimore, MD 21224, USACarlo RagoT.-C. He, C. Rago, B. Vogelstein, Howard Hughes Medical Institute and Johns Hopkins Oncology Center, 424 North Bond Street, Baltimore, MD 21231, USA. A. B. Sparks, H. Hermeking, L. Zawel, K. W. Kinzler, Johns Hopkins Oncology Center, Baltimore, MD 21231, USA. L. T. da Costa, Program in Human Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. P. J. Morin, National Institute on Aging, Baltimore, MD 21224, USAHeiko HermekingJohns Hopkins MedicineLeigh ZawelT.-C. He, C. Rago, B. Vogelstein, Howard Hughes Medical Institute and Johns Hopkins Oncology Center, 424 North Bond Street, Baltimore, MD 21231, USA. A. B. Sparks, H. Hermeking, L. Zawel, K. W. Kinzler, Johns Hopkins Oncology Center, Baltimore, MD 21231, USA. L. T. da Costa, Program in Human Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. P. J. Morin, National Institute on Aging, Baltimore, MD 21224, USALuís Teixeira da CostaT.-C. He, C. Rago, B. Vogelstein, Howard Hughes Medical Institute and Johns Hopkins Oncology Center, 424 North Bond Street, Baltimore, MD 21231, USA. A. B. Sparks, H. Hermeking, L. Zawel, K. W. Kinzler, Johns Hopkins Oncology Center, Baltimore, MD 21231, USA. L. T. da Costa, Program in Human Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. P. J. Morin, National Institute on Aging, Baltimore, MD 21224, USAPatrice J. MorinJohns Hopkins MedicineBert VogelsteinJohns Hopkins MedicineKenneth W. KinzlerT.-C. He, C. Rago, B. Vogelstein, Howard Hughes Medical Institute and Johns Hopkins Oncology Center, 424 North Bond Street, Baltimore, MD 21231, USA. A. B. Sparks, H. Hermeking, L. Zawel, K. W. Kinzler, Johns Hopkins Oncology Center, Baltimore, MD 21231, USA. L. T. da Costa, Program in Human Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. P. J. Morin, National Institute on Aging, Baltimore, MD 21224, USA
1998en

Ochiq kirish: yoʻq

ABI

Annotatsiya

The adenomatous polyposis coli gene (APC) is a tumor suppressor gene that is inactivated in most colorectal cancers. Mutations of APC cause aberrant accumulation of beta-catenin, which then binds T cell factor-4 (Tcf-4), causing increased transcriptional activation of unknown genes. Here, the c-MYC oncogene is identified as a target gene in this signaling pathway. Expression of c-MYC was shown to be repressed by wild-type APC and activated by beta-catenin, and these effects were mediated through Tcf-4 binding sites in the c-MYC promoter. These results provide a molecular framework for understanding the previously enigmatic overexpression of c-MYC in colorectal cancers.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba